Cell Therapy for Neurodegenerative Diseases

Cell Therapy for Neurodegenerative Diseases

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Cell Therapy for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Program</td>
<td>Company</td>
</tr>
<tr>
<td class="label">iPSC dopaminergic neurons</td>
<td>Kyoto University/iPS Japan</td>
</tr>
<tr>
<td class="label">iN-Dopa</td>
<td>BlueRock Therapeutics</td>
</tr>
<tr>
<td class="label">NSI-566</td>
<td>Neuralstem</td>
</tr>
<tr>
<td class="label">Astron-001</td>
<td>Astron</td>
</tr>
<tr>
<td class="label">HESC-derived DA neurons</td>
<td>Novo Nordisk</td>
</tr>
</table>

Cell Therapy for Neurodegenerative Diseases

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Cell Therapy for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Program</td>
<td>Company</td>
</tr>
<tr>
<td class="label">iPSC dopaminergic neurons</td>
<td>Kyoto University/iPS Japan</td>
</tr>
<tr>
<td class="label">iN-Dopa</td>
<td>BlueRock Therapeutics</td>
</tr>
<tr>
<td class="label">NSI-566</td>
<td>Neuralstem</td>
</tr>
<tr>
<td class="label">Astron-001</td>
<td>Astron</td>
</tr>
<tr>
<td class="label">HESC-derived DA neurons</td>
<td>Novo Nordisk</td>
</tr>
</table>

Cell therapy represents a fundamentally different approach to treating neurodegenerative diseases by transplanting living cells into the brain to replace lost [neurons](/entities/neurons), provide trophic support, or modulate the immune system. While still largely experimental, this modality offers the unique potential to regenerate damaged neural circuits—a goal no other therapeutic approach can achieve["@barker2023"]. The field has evolved from early experiments with fetal tissue transplantation to sophisticated approaches using induced pluripotent stem cells (iPSCs) and engineered cell populations.

Mechanism of Action

Cell therapies work through several mechanisms:

Neuronal Replacement

• Transplanting neurons or neuronal progenitors to replace lost cells
• Establishing synaptic connections with host neurons
• Restoring neural circuit function

Glial Cell Replacement

• Providing healthy [microglia](/cell-types/microglia-neuroinflammation) to replace dysfunctional cells
• Supporting neuronal survival and function
• Modulating the brain immune environment

Trophic Factor Delivery

• Cells engineered to secrete neurotrophic factors
• Supporting survival of endogenous neurons
• Promoting plasticity and repair

Immunomodulation

• Regulatory immune cells to dampen neuroinflammation
• Modulating the brain's immune response
• Reducing toxic inflammation

Clinical Programs

Stem Cell Approaches

Key Development Programs

Parkinson's Disease

• iPSC-derived dopaminergic neurons: Clinical trials underway in Japan using patient-derived iPSCs[@takahashi2023]
• Allogeneic hESC-derived neurons: BlueRock Therapeutics and others in early trials
• Mesenchymal stem cells: Immunomodulatory and trophic effects

• Neural progenitor cells: Phase 2 trial showed possible slowed progression[@glass2016]
• MSC-NTF cells: Phase 1/2 showing safety and potential efficacy
• iPSC-derived motor neurons: Preclinical

• Cholinergic neurons: Early development
• Glial progenitor cells: Myelin repair and neuroprotection
• Microglial replacement: Aspen Neuroscience program

Encapsulated Cell Biodelivery

• NTC-200: Encapsulated cells secreting GDNF-like factors
• Cellular "factories": Engineered to produce therapeutic proteins
• Advantages: Avoids immunosuppression, retrievable

Advantages

Cellular Replacement

• Potential to replace lost neurons
• Restore neural circuit function
• Address root cause of neuronal loss

Trophic Support

• Continuous delivery of protective factors
• Support endogenous repair mechanisms
• Promote synaptic plasticity

Disease Modeling

• Patient-derived iPSCs enable disease modeling
• Drug screening in patient-derived cells
• Personalized medicine potential

Immunomodulation

• Address neuroinflammation component
• Modulate microglial function
• Reduce toxic immune responses

Autologous Cells

• iPSC-derived cells from patient
• Avoid immune rejection
• Personalized therapy potential

Limitations

Tumor Risk

• Undifferentiated stem cells may form teratomas
• Malignant transformation possible
• Rigorous purification required

Immune Rejection

• Allogeneic cells face immune attack
• Immunosuppression required
• Autologous iPSCs avoid this issue but are expensive

Delivery Challenges

• Invasive neurosurgical procedures
• Precise placement critical
• Limited distribution within brain

Survival and Integration

• Host environment may be hostile
• Limited survival in disease brain
• Functional integration challenging

Manufacturing Complexity

• Autologous iPSC approaches costly and time-consuming
• Scalability challenges
• Quality control for each batch

Limited Efficacy Data

• Early-stage trials
• Clinical benefit not yet demonstrated
• Long-term outcomes unknown

Cell Types

Embryonic Stem Cells (ESCs)

• Pluripotent, can become any cell type
• Well-characterized
• Ethical considerations
• Allogeneic use potential

Induced Pluripotent Stem Cells (iPSCs)

• Patient-derived, avoid immune issues
• Reprogrammed from adult cells
• Personalized medicine potential
• Cost and time-intensive

Mesenchymal Stem Cells (MSCs)

• Immunomodulatory properties
• Easy to obtain (bone marrow, adipose)
• Trophic factor secretion
• Limited differentiation potential

Neural Progenitor Cells (NPCs)

• Already committed to neural lineage
• Safer than pluripotent cells
• Limited expansion capacity

Engineered Cells

• Chimeric antigen receptor (CAR) cells
• Gene-edited cells
• Synthetic biology approaches

Future Directions

Gene Editing

• Correcting genetic mutations in patient-derived cells
• Engineering enhanced therapeutic properties
• Creating "universal" donor cells

3D Culture and Organoids

• Brain organoids for drug screening
• Patient-specific disease modeling
• Therapeutic testing platforms

Combination Approaches

• Cell therapy + small molecule
• Cell therapy + gene therapy
• Multiple cell types

Delivery Innovation

• Stereotactic injection improvements
• Intravascular delivery with brain shuttles
• Minimally invasive approaches

Cross-Links

• [Therapeutic Modalities Overview](/therapeutics/therapeutic-modalities)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Dopamine](/neurotransmitters/dopamine)
• [Microglia](/cell-types/microglia)
• [Induced Pluripotent Stem Cells](/mechanisms/ipsc-derivation-neurodegeneration)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12
• [Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: ST3GAL2/ST8SIA1
• [Synthetic Biology BBB Endothelial Cell Reprogramming](/hypothesis/h-84808267) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: TFR1, LRP1, CAV1, ABCB1
• [Complement C1q Mimetic Decoy Therapy](/hypothesis/h-1fe4ba9b) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: C1QA

Related Analyses:

• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) &#x1f504;
• [Senolytic therapy for age-related neurodegeneration](/analysis/SDA-2026-04-01-gap-013) &#x1f504;